Burlingame, July 25, 2023 (GLOBE NEWSWIRE) -- Coherent Market Insights published a report, titled, “Leptospirosis Market, by Drug (Amoxicillin, Azithromycin, Cefixime, Doxycycline, Others (Ceftriaxone,Penicillin among others)), by Diagnosis (Complete Blood Count (CBC), Creatine Kinase, Liver Enzymes, Urinalysis, Others (Lumbar puncture, Microscopic agglutination test among others)), by Route of Administration (Oral, Parenteral, Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030” According to the report, Global Leptospirosis Market is estimated to be valued at US$ 496.8 million in 2023 and is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030).
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/5761
Analysts’ Views on Global Leptospirosis Market:
Increasing number of patients affected with Leptospirosis is expected to rise the demand for treatment options which can be a driving factor for the growth of Global Leptospirosis Market in near future. For instance, data published by The European Centre for Disease Prevention and Control stated that in the year 2020- 21 EU/EEA countries reported 907 leptospirosis cases of which 565 (62%) were classified as confirmed. The remaining 342 cases (38%) were reported as probable. France reported 323 (94%) of the 342 probable cases. Four countries (France, Germany, the Netherlands, and Portugal) accounted for 66% of all notified cases, although their combined populations only represent approximately 34% of the total population of the EU/EEA. Thus this is expected to rise the demand for drugs for treatment of Leptospirosis in the near future which can drive the growth of the market.
Global Leptospirosis Market Segmentation:
The Global Leptospirosis Market report is segmented into Drug, Diagnosis, Route of Administration and Distribution Channel
Based on Drug, the market is segmented into Amoxicillin, Azithromycin, Cefixime, Doxycycline, Others (Ceftriaxone, Penicillin among Others). Out of which Amoxicillin segment is expected to dominant position in Leptospirosis Market during the forecast period and this is attributed due to increase in use of Amoxicillin for the treatment of Leptospirosis, as Amoxicillin drug is the used as off label treatment option by various government authorities
Based on Diagnosis, the market is segmented into Complete Blood Count (CBC) , Creatine Kinase.Liver Enzymes, Urinalysis, Others (Lumbar puncture, Microscopic agglutination test among others)). Out of which Complete Blood Count (CBC) segment is expected to dominant position in Leptospirosis Market during the forecast period and this is attributed due to increase in use for the Complete Blood Count (CBC) as diagnosis option for Leptospirosis by various hospitals, diagnosis centrs and others
Based on Route of Administration, the market is segmented into Oral, Parenteral, Intravenous. Out of which, hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to the increase in the use of Oral medicines as treatment option for Leptospirosis
Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to the increase in the number of hospital pharmacies.
Among all segmentation, drug segment has the highest potential due to the increasing demand for drugs for the treatment of Leptospirosis.
Leptospirosis Market Report Coverage
Report Coverage | Details | |||
Base Year: | 2022 | Market Size in 2023: | US$ 496.8 Mn | |
Historical Data for: | 2017 to 2021 | Forecast Period: | 2023 to 2030 | |
Forecast Period 2023 to 2030 CAGR: | 5.8% | 2030 Value Projection: | US$ 739.6 Mn | |
Geographies covered: |
| |||
Segments covered: |
| |||
Companies covered: | USAntibiotics, Dr. Reddy’s Laboratories Ltd., Century Pharmaceuticals Ltd., Mayne Pharma Group Limited, Sun Pharmaceutical Industries, Inc., Ralington Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sandoz International GmbH, ISKON REMEDIES & GMT, Haustus Biotech Pvt. Ltd., and Aden Healthcare | |||
Growth Drivers: |
| |||
Restraints & Challenges: |
|
Request Customization of this Report @ https://www.coherentmarketinsights.com/insight/request-customization/5761
Cross Sectional Analysis of Global Leptospirosis Market:
Among drug, the amoxicillin segment is dominant in Europe due to increasing demand for amoxicillin for the treatment of leptospirosis over the forecast period. For instance, In October 2022, Médecins Sans Frontières (MSF), an international independent medical humanitarian organization, that provides medical assistance to people affected by epidemics issued guidelines for treatment options such as amoxicillin PO for 7 days, children: 25 mg/kg (max. 1 g) 2 times daily, adults: 1 g 2 times daily
Key Market Takeaways:
The Global Leptospirosis Market is expected to exhibit a CAGR of 5.8% during the forecast period due to the increasing awareness campaign by the key market players to raise awareness. For instance, on April 13, 2022, the health department launched a campaign, in Kerala, India, to promote awareness of leptospirosis. The government suggested that people engaged in farming and cleaning activities should necessarily wear safety gloves and boots.
Competitive Landscape:
Key players operating in the Global Leptospirosis Market include USAntibiotics, Dr. Reddy’s Laboratories Ltd., Century Pharmaceuticals Ltd., Mayne Pharma Group Limited, Sun Pharmaceutical Industries, Inc., Ralington Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sandoz International GmbH, ISKON REMEDIES & GMT, Haustus Biotech Pvt. Ltd., and Aden Healthcare
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/5761
Market Segmentation:
- Global Leptospirosis Market, By Drug:
- Amoxicillin
- Azithromycin
- Cefixime
- Doxycycline
- Others (Ceftriaxone,Penicillin among others)
- Global Leptospirosis Market, By Diagnosis:
- Complete Blood Count (CBC)
- Creatine Kinase
- Liver Enzymes
- Urinalysis
- Others (Lumbar puncture, Microscopic agglutination test among others)
- Global Leptospirosis Market, By Route of Administration:
- Oral
- Parenteral
- Intravenous
- Global Leptospirosis Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Leptospirosis Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- North America
Related Market Intelligence Reports:
Regenerative Therapies Market, By Tissue Type (Allograft, Xenograft, Alloplast), By Application type (Soft Tissue Repair, Cardiovascular, Dental, Orthoped, CNS disease treatment,Others), By End user (Hospitals, Ambulatory Surgical Centers, Educational Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
Anti-Osteoporosis And Fracture Healing Market, by Drug Class (Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic acid), Hormone replacement therapy (Estrogen, Progestin, Others), Monoclonal Antibodies (Denosumab, Romosozumab), Anabolic Agents (Alendronate, Teriparatide), and Others), by Route of Administration (Oral and Injection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.